natgillin/translations-raw huggingface dataset:
and/or, in step (2), the mole ratio of the base to compound 4 is in the range of 0.1-0.2; 
i / ili, u koraku (2), molni omjer baze prema spoju 4 je u rasponu 0,1-0,2;
a nucleotide sequence encoding a polypeptide having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:2, 4, or 6, wherein said polypeptide has glyphosate-tolerance activity; and, 
nukleotidni odsječak koji kodira polipeptid koji ima najmanje 80% identitet odsječka aminokiselinkom odsječku SEQ ID NO: 2, 4 ili 6, pri čemu rečeni polipeptid ima aktivnost tolerancije na glifosat; i
BRIEF SUMMARY Technical Problem In the SU-MIMO communications, when transmitting control information in a PUSCH, the amount of the resource required to allocate control information (ACK/NACK signals) is determined based on the coding rate of one of the two CWs, just as in the LTE system (for example, Non-Patent Literature 1). 
Postupak prijenosa za prijenos kontrolne informacije u pluralitetu slojeva, postupak sadržeći: određivanje količine resursa kontrolne informacije u pluralitetu slojeva; 1 prijenos kontrolne informacije na temelju količine resursa kontrolne informacije, naznačeno time da je količina resursa Qowso+cwsr kontrolne informacije određena jednadžbom 1: r t
An in vitro method according to any of the preceding claims, wherein the total concentration of first full-length antibody and second full-length antibody in step a) is at least 0.25 mg/mL. 
Postupak in vitro prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da ukupna koncentracija od prvog protutijela pune duljine i drugog protutijela pune duljine u koraku a) iznosi najmanje 0,25 mg/mL.
cooling said formed insulation block, and 
nastali izolacijski blok se hladi, i -
A compound according to claim 1, wherein said compound has the structural formula Ib, Ic or Id 
Spoj u skladu s patentnim zahtjevom 1, naznačeno time što navedeni spoj ima strukturnu formulu Ib, Ic ili Id [image]
The composition of claim 4, wherein the gelling agent comprises hydroxypropyl cellulose. 
Pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što sredstvo za geliranje sadrži hidroksipropil celulozu.
A composition or vaccine comprising a first recombinant herpesvirus of turkeys (HVT) vector comprising a heterologous polynucleotide coding for and expressing a Newcastle Disease Virus F (NDV-F) antigen operably linked to an SV40 promoter and an SV40 polyA signal, further wherein the polynucleotide encoding the NDV-F polypeptide, the operably linked SV40 promoter and SV40 polyA signal are inserted in the intergenic site 1 (IG1) locus of HVT genome, further wherein the polynucleotide coding for and expressing NDV-F has the sequence as set forth in SEQ ID NO: 1; and 
Pripravak ili cjepivo, naznačen/o time, da obuhvaća prvi rekombinantni vektor herpesvirusa purana (HVT – engl. herpesvirus of turkey), koji obuhvaća heterologni polinukleotid koji kodira za ili eksprimira antigen virusa F Newcastleske bolesti (NDV-F), koji je operativno povezan sa SV40 promotorom i SV40 poliA-signalom, i nadalje time, da su polinukleotid koji kodira NDV-F polipeptid, te operativno povezani SV40 promotor i SV40 poliA-signal, umetnuti u intergensko mjesto 1 (IG1 lokus) od HVT genoma, te nadalje, time, da polinukleotid koji kodira za ili eksprimira NDV-F, ima sekvencu koja je prikazana u SEQ ID BR:1; i drugi rekombinantni HVT vektor koji obuhvaća heterologni polinukleotid koji kodira za ili eksprimira antigen VP2 virusa infektivnog bursitisa (IBDV – engl.
Also suitable are polyethyleneglycol castor oils such as that available under the trade name CREMOPHOR EL. 
Također su prikladna polietilenglikol ricinusova ulja poput onih raspoloživih pod zaštićenim nazivom CREMOPHOR EL.
To a solution of compound 8a (30 mg, 0.048 mmol) in DCM (1 mL) was added TFA (0.1 mL, 1.3 mmol) and stirred at room temperature for 1.5 hours. 
U otopinu spoja 8a (30 mg, 0,048 mmol) u DCM-u (1 ml) doda se TFA (0,1 ml, 1,3 mmol), te miješa 1,5 sati na sobnoj temperaturi.
wherein n is an integer from 1 to 20 such as, e.g., from 2 to 20, from 3 to 20, from 1 to 15, from 2 to 15, from 3 to 15, from 1 to 10, from 2 to 10, from 3 to 10, or from 4 to 9, wherein R is R1R2N—, R1O—, or R1S—, 
Jedan ili više oligomera mliječne kiseline za uporabu prema patentnom zahtjevu 1, pri čemu je n od 2 do 20, od 3 do 25, od 3 do 20, od 2 do 15, od 3 do 15, od 2 do 10, od 3 do 10, od 4 do 10, ili od 4 do 9.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the extended release matrix formulation after having been stored at 25°C and 60 % relative humidity (RH), preferably at 40°C and 75 % relative humidity (RH), for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 6, gdje formulacija matrice s produljenim otpuštanjem nakon skladištenja na 25°C i 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, kada je mjerenje provedeno u USP aparatu 1 (košara) pri 100 okr/min u 900 ml simulirane želučane tekućine bez enzima (SGF) pri 37°C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1,4 i 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
The residue is filtered, and the solution yields (2') as a light colored crystalline solid. 
Ostatak je filtriran, a iz otopine je dobiven (2') kao svjetlo obojena krinstalinična krutina.
A composition comprising a recombinant glycosylated human Serum Amyloid P (SAP) polypeptide comprising an N-linked oligosaccharide chain, wherein at least one branch of the oligosaccharide chain terminates with an a2,3-linked sialic acid moiety, and wherein the composition has at least 50% fewer a2,6-linked sialic acid moieties than wild type SAP isolated from human serum. 
Farmaceutski pripravak, naznačen time, da sadržava rekombinantni glikolizirani humani serumski amiloidni P (SAP) polipeptid koji sadržava N-vezani oligosaharidni lanac, pri čemu barem jedna grana oligosaharidnog lanca završava s 02,3-vezanim ostatkom sijalične kiseline i pri čemu smjesa ima najmanje 50% manje a2,6-vezanih ostataka sijalinske kiseline od divljeg tipa SAP izoliranog iz humanog seruma.
A device for producing a beverage from a capsule, comprising: an extraction module comprising a first jaw member and a cooperating second jaw member, in an opened state of the extraction module the first jaw member and the cooperating second jaw member are separated from each other while in the closed state the first jaw member and the cooperating second jaw member are in contact; 
- - modul za ekstrakciju koji ima prvi element čeljusti (6) i drugi element čeljusti (7) koji djeluje zajedno s prvim elementom čeljusti, pri čemu su u otvorenom položaju modula za ekstrakciju elementi čeljusti (6, 7) razmaknuti jedan od drugoga, dok su u zatvorenom položaju elementi čeljusti (6, 7) u čvrstom kontaktu,
The pharmaceutical composition according to anyone of claims 4 to 8, wherein said composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 23, naznačen time što je u obliku tablete, kapsule, praška, peleta, suspenzije, emulzije, kreme, gela, masti ili paste.
The reaction was stirred at 50°C for 6 hrs and then stirred at RT overnight. 
Reakcijska smjesa je miješana na 50%C kroz 6 sati i tada miješana na sobnoj temperaturi tijekom noći.
All patents, publications and references cited herein are hereby fully incorporated by reference. In case of conflict between the present disclosure and incorporated patents, publications and references, the present disclosure should control. Pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis (TPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day or 1602 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 -puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 1600 mg/dan ili 1602 mg/dan.
a QAM demapper (r713-C) configured to demap the deinterleaved constellation values into cell words and to multiplex the demapped cell words into PLP data; 
QAM demaper konfiguriran za demapiranje raspletenih konstelacijskih vrijednosti u stanične riječi i za multipleksiranje demapiranih staničnih riječi u PLP podatke; dio za raspletanje bitova konfiguriran za raspletanje bitova multipleksiranih PLP podataka;
is independently selected from H, F, Cl, and OCH3; is independently selected from H, cyano, C1-4 alkyl, haloalkyl, and halogen; and 
R? je nezavisno odabrano od H, cijano, C1.4 alkil, haloalkil, i halogen; i n, u svakom slučaju, je cijeli broj izabran od 1 12.
A glassy lozenge according to claim 22, wherein the buffering agents comprise one or more phosphate salts. 
Tableta-pastila prema patentnom zahtjevu 23, naznačena time što puferska sredstva sadrže jednu ili više fosfatnih soli.
The pharmaceutical composition of claim 7; wherein the partial structure of formula (I) within structure (A) of claim 7, which is 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je djelomična struktura od sljedeće formule (1) koja je unutar strukture (A) prema zahtjevu 1:
Mechanical bonding in enamel prisms and dentin dentin tubuli. 
Mehaničko vezanje u prizmama cakline i dentinskih tubula.
As the active ingredient of the medicament of the present invention, a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof. 
Kao aktivni sastojak lijeka prema ovom izumu može se upotrijebiti tvar koju se bira iz skupine koju čine spoj prikazan gore navedenom formulom (1) i njegove farmakološki prihvatljive soli, te njihovi solvati i hidrati.
the Cas9 protein is introduced in the form of a protein, a messenger RNA (mRNA) encoding the Cas9 protein, or a DNA encoding the Cas9 protein; 
Cas9 protein je introduciran u obliku proteina, informacijske RNA (iRNA) koja kodira Cas9 protein, ili DNA koja kodira Cas9 protein;
Currently, the oral therapy of intestinal infections, and in particular colon infections, uses substances having antibacterial activity which must have specific characteristics such as: broad spectrum of activity on Gram+and Gram- bacteria, resistance to strongly acidic environments, such as the gastric environment, anti-infectious activity independent of the presence of the intestinal biomass, residence inside the intestine for an appropriate period of time, good penetrability into the infecting host cell and good tolerability (Braga PC. 
Trenutno se za oralno liječenje crijevnih infekcija, posebno infekcija kolona, koriste tvari antibakterijskog djelovanja specifičnih karakteristika kao što su: široki spektar djelovanja na Gram+ i Gram- bakterije, otpornost na uvjete jake kiselosti kao što su uvjeti u gastričkom okolišu, antiinfektivno djelovanje neovisno o prisustvu crijevnih biomasa, ostajanje unutar crijeva kroz odgovarajući period vremena, dobra penetrabilnost u inficiranu stanicu domaćina 1 dobra tolerancija (Braga PC.
The composite stainless steel and wood barrel according to one of claims 1 to 4, wherein the barrel comprises a plurality of wooden slats (6) and a plurality of slats made of inert materials. 
Kombinirana bačva od nehrđajućeg čelika 1 drva, prema jednom od patentnih zahtjeva 1 do 4, naznačena time da bačva sadrži veći broj drvenih daščica (6) 1 veći broja daščica od inertnih materijala.
An FGF-18 compound for use in the treatment of a cartilage disorder wherein the FGF-18 compound is to be administered for at least 3 consecutive weeks per treatment cycle, said administrations being separated by about at least 6, 7 or 8 days. 
PATENTNI ZAHTJEVI Spoj FGF-18 za uporabu kod liječenja poremećaja hrskavice naznačen time da se spoj FGF-18 daje tijekom barem 3 uzastopna tjedna po ciklusu terapije, te su navedena davanja odvojena sa oko najmanje 6, 7 ili 8 dana,
Use according to one of the claims 8, 9 or 10 wherein the patient is an individual with insufficient glycemic control despite monotherapy with a DPP IV inhibitor, in particular a DPP IV inhibitor according to claim 1, 3 or 4. 
Farmaceutski sastav za uporabu prema zahtjevu 11, 12 ili 13, naznačen time, da je pacijent pojedinac s nedovoljnom glikemijskom kontrolom usprkos monoterapiji s DPP IV-inhibitorom, posebno s DPP IV-inhibitorom prema zahtjevu 1.
wherein the base and the continuous side wall consist essentially of polyethylene terephthalate (PET), 
Posuda prema patentnom zahtjevu 1, pri čemu su osnova i kontinuirani bočni zid prozirni.
a lower element made of plastic material, on which a tread provided with a plurality of through holes is formed; 
- < donji element (11, 111, 211, 311) izrađen od plastičnog materijala, na kojem se nalazi gazište (12) s većim brojem perforiranih rupa (13);
A compound represented by formula (II), or a pharmaceutically acceptable salt thereof or a solvate thereof: (wherein 
Spoj, naznačen time, da je predstavljen formulom (Il), ili njegova farmaceutski prihvatljiva sol ili njegov solvat: iKennjska formula 4]
The method of item 25, wherein the step of purifying comprises depth filtration of the filtered fraction to produced a clarified extract, followed by chromatography of the clarified extract using a cation exchange resin, a size exclusion resin, an affinity resin, or a combination thereof. 
Postupak sukladno patentnom zahtjevu 9 ili 13, naznačen time, da korak pročišćavanja obuhvaća filtriranje frakcije filtriranjem dubine da se dobije pročišćeni ekstrakt, nakon čega slijedi kromatografija pročišćenog ekstrakta upotrebom kromatografije isključenja veličine, kationske izmjenjivačke smole ili afnitetne kromatografije 11 njihove kombinacije.
Controller 80 would also instruct pump 40 to operate, but in a reverse flow mode. 
Kontrolor 80 će aktivirati pumpu 40 tako da radi u suprotnom smjeru.
Mixtures comprising compounds (4) and (5); 
smjese koje sadrže spojeve (4) i (5);
adding an aqueous solution of a mineral acid, such as hydrochloric acid for example, thereby providing a compound of formula (9b): 
dodavanje vodene otopine mineralne kiseline, čime se dobiva spoj formule (9b):
The resulting suspension is filtered and the filter cake washed three times with water and dried over night at 40°. 
Rezultirajuća suspenzija se filtrira, talog nakon filtriranja se ispere tri puta vodom i suši preko noći na 40 *C .
at least one blood sample from said patient is to be collected within the first 3 months of treatment, the plasma trough level (Cmin) of Imatinib is to be determined, and the dose of Imatinib or a pharmaceutically acceptable salt thereof is to be adjusted in a manner that a Cmin between 1000 and 3000 ng/mL of Imatinib is achieved, wherein the patient does not reach a Cmin between 1000 and 3000 ng/mL of Imatinib after administration of the predetermined fixed amount of the mono-mesylate salt of Imatinib. 
(b) sakuplja barem jedan uzorak krvi od spomenutog pacijenta unutar prva tri mjeseca liječenja, (c) određuje lokalni minimum razine plazme (Crmin) imatiniba, i (d) podešava doza imatiniba ili njegove farmaceutski prihvatljive soli na takav način da se postigne Cmin imatiniba između 1000 i 3000 ng/mL, pri čemu pacijent ne dosegne Cmin između 1000 i 3000 ng/mL imatiniba nakon davanja predodređene fiksne količine mono-mesilatne soli imatiniba.
and P5 are carboxyl protecting groups. 
P, i Ps su karboksilne zaštitne skupine.
ADM antibody or an adrenomedullin antibody fragment or ADM non-IG scaffold for use in therapy of a chronic or acute disease of a patient according to any of embodiments 1 to 9 wherein said patient is an ICU patient. ADM antibody or an adrenomedullin antibody fragment or ADM non-IG scaffold for use in therapy of a chronic or acute disease of a patient according to any of embodiments 1 to 12 wherein said antibody or fragment or scaffold is a modulating antibody or fragment or scaffold that enhances the half life (t1/2 half retention time) of adrenomedullin in serum, blood, plasma at least 10%, preferably at least 50%, more preferably >50%, most preferably >100% and that blocks the bioactivity of ADM to less than 80%, preferably less than 50%. 
Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 9, pri čemu spomenuto antitijelo ili fragment ili skela je modulirajuće anti-ADM antitijelo ili modulirajući anti-adrenomedulin fragment antitijela ili modulirajuća anti-ADM non-Ig skela koja povećava polu-život, t1/2 polu retencijsko vrijeme, adrenomedulina u serumu, krvi, plazmi barem 10 %, ili barem 50 % ili > 50 % ili > 100 % i koja blokira bioaktivnost ADM na ne više od 80 %, poželjno ne više od 50 % kada se bioaktivnost ADM u humanom rekombinantnom Adrenomedulin receptoru cAMP određuje funkcionalnom analizom prema Primjeru 2.
Biomaterials as claimed in the preceding claims for use as new fillers and/or as new products for body shaping in the treatment of skin blemishes, in dermatology, in dermocosmetology and/or in aesthetic surgery. 
Biomaterijali kako su prijavljeni u prethodnim patentnim zahtjevima, naznačeni time da se koriste za nova punila i/ili novi produkti za oblikovanje tijela i tretman mrlja na tijelu u dermatologiji, u dermokozmetologiji i/ili estetskoj kirurgiji. ns ran mona og mmoa
reacting compound E4 with hydrogen in the presence of acetic anhydride to form compound E5 and 
Eđ reakcijom navedenog oksima E4 s anhidridom octene kiseline i vodikom uz prisutnost katalizatora hidrogenizacije.
Suitable compounds of the invention are: 
Broj objave europskog patenta:
In some embodiments, the bispecific antibody specifically binds human DLL4, and comprises: a heavy chain variable region having at least 90% sequence identity to SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:58, or SEQ ID NO:64; and/or a light chain variable region having at least 90% sequence identity to SEQ ID NO:12. 
(b) drugo varijabilno područje teškog lanca koje ima najmanje 90% identiteta sekvence od SEQ ID NO: 64, SEQ ID NO: 9, SEQ ID NO: 10 ili SEQ ID NO: 58; 1 (c) prvo i drugo varijabilno područje lakog lanca, koja imaju najmanje 90% identiteta sekvence od SEQ ID NO: 12.
An aptamer identified according to the method of paragraph 37. The aptamer of paragraph 53 wherein said aptamer has a rate of dissociation (t1/2) from its target molecule of greater than or equal to about 30 minutes. 
Ne-kovalentni kompleks prema zahtjevu 6, naznačen time, da je brzina razdruživanja (ti/2) aptamera iz ciljane molekule, veća ili jednaka vremenu od 30 minuta.
In this invention post consumer flakes that have significantly lower starting IV, i.e. higher than 0.6 ml/g, preferably higher than 0.65 ml/g, have been used, where by means of reactive foam extrusion the IV of the polymer is increased in a single step to a satisfactory level while at the same time a physical blowing agent is introduced to the mixture. 
Postupak prema patentnom zahtjevu 5, naznačen time da je intrinzična viskoznost post-potrošačke PET smole viša od 0.6 ml / g, poželjno viša od 0.65 mL / g, te se viskoznost post-potrošačke smole povećava pomoću produženog lanca, reaktivnih aditiva tijekom procesa miješanja.
optionally substituted heterocyclo; and 
0) - opcionalno supstituiranog cikloalkila;
Use according to any one of claims 10, 18 and 19 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia. 
B2 agonist za uporabu prema zahtjevu 18 naznačen time, da pacijent pati od postojećeg stanje srca ili stanja koje će biti pogoršano tahikardijom.
forming polypropiolactone at a first location, comprising contacting beta-propiolactone with a polymerization catalyst comprising an acrylate anion; 
dobivanja polipropiolaktona na prvoj lokaciji, koje se sastoji u stavljanju u kontakt B-propiolaktona s katalizatorom polimerizacije koji sadrži akrilatni anion;
The preferred library contains immunoglobulins according to the invention, selected from the group consisting of domains of an immunoglobulin, minidomains or derivatives thereof. 
Postupak u skladu sa zahtjevom 15 do 17, naznačen time, da je imunoglobulin izabran iz skupine koju čine IgA1, 12A2, IgD, IgE, IgG1, 12G2, IgG3, IgG4 i IgM.
wherein R1, R2 and X is as described above for the formula (I); and an amine of formula (III): 
gdje su Ri, R21 X kao što su gore opisani za formulu (I); i amina formule (III): HR P20120715 TI
The anti-C5 antibody for use according to any one of claims 1 to 13, wherein said anti-C5 antibody is eculizumab or pexelizumab; wherein said inhibitor of IL-2 is selected from the group consisting of cyclosporine A, tacrolimus, and sirolimus; and wherein said immunosuppressive drug is LF15-0195. 
Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 13, naznačeno time, što je spomenuto anti-C5 antitijelo ekulizumab ili pekselizumab; pri čemu se spomenuti inhibitor IL-2 bira iz grupe koja se sastoji od ciklosporina A, takrolimusa 1 sirolimusa; i pri čemu je spomenuti imunosupresivni lijek LF15- 0195.
wherein a compound of formula (6): 
(I AD, navedeni spoj s formulom (6):
Process as claimed in claim 1, wherein the formula I is prepared where 
Postupak u skladu s patentnim zahtjevom 1, gdje se dobiva spoj formule I, naznačen time što
Use of a compound according to any one of claims 1-22, in the preparation of a medicament for the treatment or prevention of a bacterial infection in a subject. 
naznačen time, da se on upotrebljava u kombinaciji s dodatnim lijekom u postupku liječenja ili prevencije bakterijske infekcije.
An antibody that specifically binds to an N-terminal epitope of AB for use in a method of treating or effecting prophylaxis of an amyloidogenic disease characterized by amyloid deposits of AB in the brain, in a patient having zero ApoE4 alleles. 
Humanizirano antitijelo prema bilo kojem od patentnih zahtjeva 1 do 4 za upotrebu u postupku liječenja ili obavljanja profilakse amiloidogene bolesti, naznačeno time da amiloidne naslage AB u mozgu kod pacijenta imaju nula ApoE4 alela.
a closure (22) formed on an upper rim (41) of said cup-shaped part (40). 
- < poklopac (22) izrađen na gornjem rubu (41) spomenutog dijela (40) oblika čašice.
Medium for use according to claim 18, wherein the human reproductive cell is an unfertilized ovum or a plurality of spermatozoa or a fertilized ovum and wherein the medium is specific for inter-uterine insemination. 
Podloga za uporabu prema patentnom zahtjevu 18, naznačena time što je humana reproduktivna stanica nefertilizirana jajna stanica ili veći broj spermatozoida ili fertilizirana jajna stanica i gdje je podloga specifična za inter-uterinsku inseminaciju.
Z is a bond or straight or branched lower alkylene); 
Z je veza, ili ravni ili razgranati niži alkilen);
Example 10: Preparation of donepezil hydrochloride polymorph I g donepezil hydrochloride were suspended in methanol (30 ml) and 0.8 ml of water, heated to 60-65°C to get a clear solution. 
Primjer 10: Priprema donepezil hidroklorida polimorfa I 5 g donepezil hidroklorida suspendirano je u metanolu (30 mL) i 0,8 mL vode, zagrijano na 60-65 "C s ciljem dobivanja bistre otopine.